Clinical outcomes and apomucin expression of intrahepatic cholangiocarcinoma according to gross morphology.
BACKGROUND
The clinicopathologic characteristics and the expression of apomucin (MUC) in intrahepatic cholangiocarcinoma (ICC) with respect to gross morphology have not been comprehensively examined.


METHODS
We reviewed the clinical data of 98 patients with ICC who underwent resection at Seoul National University Hospital from 1980 to 1998. We also examined the expression profiles of MUC1 and MUC2 in 30 ICC tissues by immunohistochemistry using mouse monoclonal antibodies.


RESULTS
Of 98 cases, 42 were of the mass-forming type of ICC, 22 were of the periductal-infiltrating type, 21 were of the intraductal-growth (IG) type, and 13 were of the mixed type, and the overall 5-year cumulative survival rate was 23.3% in the mass-forming type, 0% in the periductal-infiltrating type, and 76.2% in the IG type. MUC1 was expressed in all types (mass-forming type 75.0%, periductal-infiltrating type 100%, and IG type 73.3%), but significantly, MUC2 was expressed only in the IG type (80.0%), which had better prognosis than the other types.


CONCLUSIONS
It is apparent that the IG type of ICC should be distinguished from the other types of ICC because a favorable prognosis can be expected after complete surgical resection.
Suh
Kyung-Suk
KS
Department of Surgery, Seoul National University College of Medicine, and Clinical Research Institute, Seoul National University Hospital, Seoul, Korea.
Chang
Seong-Hwan
SH
Lee
Hyuk-Joon
HJ
Roh
Hye Rin
HR
Kim
Seong Hoon
SH
Lee
Kuhn Uk
KU
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D018281:Cholangiocarcinoma / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009077:Mucins / Q000378:metabolism*; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D009077:Mucins